A carregar...
Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens
Fosaprepitant dimeglumine (Emend IV(®)) is an IV antiemetic that may be beneficial to patients receiving highly emetogenic regimens. Aprepitant (Emend(®)) is an oral medication that is administered for three consecutive days, whereas fosaprepitant is a single-dose IV medication that is administered...
Na minha lista:
| Publicado no: | Clin J Oncol Nurs |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510647/ https://ncbi.nlm.nih.gov/pubmed/27668376 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1188/16.CJON.555-556 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|